Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial.

King, Brett; Ehst, Benjamin; Foley, Peter; Reygagne, Pascal; Ohyama, Manabu; Szepietowski, Jacek C; Popmihajlov, Zoran; De Leonardis, Francesco; Hippeli, Lauren; Treitel, Michelle; Johnson, Brandon; Gilvary, Coryandar; Vaile, John; Daamen, Carolin; Passeron, Thierry

doi:10.1093/bjd/ljag109

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial.

2026-03-30, The British Journal of Dermatology (10.1093/bjd/ljag109) (online)
Brett King, Benjamin Ehst, Peter Foley, Pascal Reygagne, Manabu Ohyama, Jacek C Szepietowski, Zoran Popmihajlov, Francesco De Leonardis, Lauren Hippeli, Michelle Treitel, Brandon Johnson, Coryandar Gilvary, John Vaile, Carolin Daamen, and Thierry Passeron (?)

Alopecia areata (AA) is a common, immune-mediated inflammatory disease characterized by non-scarring hair loss. Tyrosine kinase 2 (TYK2) mediates signaling of select proinflammatory cytokines (e.g. IL-12, IL-23, and Type I interferons), which may play a role in the pathogenesis of AA.

This article has not yet been included in any curations.

Comments

There are no comments on this article yet.

You need to login or register to comment.

BioSothis

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial.